Skip to main content

Tascenso ODT FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 9, 2023.

FDA Approved: Yes (First approved December 23, 2021)
Brand name: Tascenso ODT
Generic name: fingolimod lauryl sulfate
Dosage form: Orally Disintegrating Tablets
Company: Cycle Pharmaceuticals Ltd.
Treatment for: Multiple Sclerosis

Tascenso ODT (fingolimod) is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing forms of multiple sclerosis (MS).

Development timeline for Tascenso ODT

DateArticle
Feb 13, 2023Tascenso ODT (fingolimod) Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support
Nov  1, 2022Cycle Pharmaceuticals to launch Tascenso ODT┬« (fingolimod) in US in Q1 2023

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.